Prosecution Insights
Last updated: November 20, 2026
Application No. 18/802,285

GAL475 COMPOSITIONS AND METHODS OF USE THEREOF

Non-Final OA §112
Filed
Aug 13, 2024
Priority
Aug 14, 2023 — provisional 63/519,310
Examiner
MARTIN, KEVIN STEPHEN
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Neurim Pharmaceuticals (1991) Ltd.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
1y 1m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
124 granted / 161 resolved
+17.0% vs TC avg
Strong +21% interview lift
Without
With
+20.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
52 currently pending
Career history
206
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
24.8%
-15.2% vs TC avg
§102
16.9%
-23.1% vs TC avg
§112
41.2%
+1.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 161 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims The amendments to the claims filed August 13, 2024 are acknowledged and entered. Claims 1-24 are pending. Priority This application claims benefit of 63/519,310 filed August 14, 2023. Information Disclosure Statement Acknowledgement is made of the Information Disclosure Statements filed on August 13 and November 14, 2024. All references have been considered except where marked with a strikethrough. Specification The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any of the errors of which applicant may become aware of in the specification. Election/Restriction The requirement for restriction set forth July 24, 2026 has been reconsidered and is hereby withdrawn. Allowable Subject Matter Claims 2 and 4-7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph. The following is a statement of reasons for the indication of allowable subject matter: The closest reference to the instant claims is Dirk et al. (EP2248523 A1)(hereinafter “Dirk”). Dirk teaches use of 2,6-Bis(diethanolamino)-4,8-diheptamethyleneimino-pyrimido[5,4-d]pyrimidine (pictured below) in the therapeutic treatment of diabetes mellitus and metabolic syndrome (see claims 1 and 2). The difference between Dirk and the instant claims is that the instant claims require that the alkyl of formula (I) is not substituted with a hydroxy group. Dirk does not teach formula (I) of the claims. There is no teaching which would have motivated a person of ordinary skill in the art before the effective filing date of the instant application to selectively modify Dirk into the claimed invention with any reasonable expectation of success. PNG media_image1.png 412 672 media_image1.png Greyscale Claim Rejections - 35 USC § 112a The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1, 3 and 8-24 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. MPEP 2163.04 states: In rejecting a claim, the examiner must set forth express findings of fact regarding the above analysis which support the lack of written description conclusion. These findings should: • (A) Identify the claim limitation at issue; and • (B) Establish a prima facie case by providing reasons why a person skilled in the art at the time the application was filed would not have recognized that the inventor was in possession of the invention as claimed in view of the disclosure of the application as filed. Analysis Prong A: In the instant case, the limitation at issue is “diabetes” as recited in claim 1. The limitation is not defined in the specification and would be understood to include both type 1 and 2 diabetes. The claimed method thus embraces treatment of both type 1 and type 2 diabetes. Analysis Prong B: State of the prior art reference Pathak et al. (Endocrinology and Diabetes 2019, Vol 12, 1-13) teaches type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells located in the endocrine pancreas in areas known as islets of Langerhans. The current standard-of-care for T1D is exogenous insulin replacement therapy. Recent developments in this field include the hybrid closed-loop system for regulated insulin delivery and long-acting insulins. Clinical studies on prediction and prevention of diabetes-associated complications have demonstrated the importance of early treatment and glucose control for reducing the risk of developing diabetic complications. Transplantation of primary islets offers an effective approach for treating patients with T1D. However, this strategy is hampered by challenges such as the limited availability of islets, extensive death of islet cells, and poor vascular engraftment of islets post-transplantation (Abstract). Pathak teaches existing interventions include insulin replacement, cell transplantation, and efforts to preserve beta cells (e.g. through immune therapies)(see Table 2). The state of the prior art thus appears to regard treatment of type 1 diabetes as being centered on replacement of insulin and methods of increasing insulin production (e.g. by cell transplantation). In the instant case, the claimed method has no reported effect on insulin production nor does it appear to increase insulin in a subject. Given the state of the prior art, a person skilled in the art would not recognize that Applicant was in possession of a method of treating diabetes as broadly as is claimed at the time the application was filed. This rejection could be overcome by amending the claims to recite “type-2 diabetes”. Support for this amendment can be found at [0135] of the specification. Claim Rejections - 35 USC § 112b The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite for the reasons that follow: Claim 1 recites a variable “L” (see PNG media_image2.png 36 280 media_image2.png Greyscale ); however, the claim does not define L. The metes and bounds of formula (I) are therefore unclear. The claim should be amended to define L (see e.g. [0014]). Claims 8-24 depend from claim 1, include the limitation L, and are indefinite for the same reason. Claims 1-24 include the limitation “isotopic variant”. This limitation is indefinite because the specification fails to provide any example of such variants or provide a general definition. The metes and bounds of “isotopic variant” are unclear. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. November 4, 2026 /K.S.M./Examiner, Art Unit 1624 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Aug 13, 2024
Application Filed
Nov 06, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788753
REPOSITIONING THE ANTI-LEPROSY DRUG CLOFAZIMINE AGAINST DRUG-RESISTANT MYELOMA AND PUTATIVE STEM-CELL SUBCLONES
3y 5m to grant Granted Nov 10, 2026
Patent 12790343
SOLID FORMS OF PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS
2y 6m to grant Granted Nov 10, 2026
Patent 12758629
N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT
4y 8m to grant Granted Oct 13, 2026
Patent 12746239
COMPOSITIONS AND METHODS COMPRISING ENDOTHELIN A RECEPTOR ANTAGONISTS AND ANDROGEN THERAPIES
4y 10m to grant Granted Sep 29, 2026
Patent 12747214
IMIDAZOLE-BASED SYNTHETIC LIPIDOIDS FOR IN VIVO MRNA DELIVERY INTO IMMUNE CELLS
4y 0m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
98%
With Interview (+20.7%)
3y 5m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 161 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month